TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 25.1nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 398nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 1/2(Homo sapiens (Human))
Astex Therapeutics
US Patent
Astex Therapeutics
US Patent
Affinity DataIC50: <1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
